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E: Enrichment of Canonical STAT3 induced genes in Ezh2 Δ/Δ Cdkn2a -/-NRASQ61K cells compared to
Ezh2 f/f Cdkn2a -/-NRASQ61K cells prior to injection.
F:
Growth of Ezh2 f/f Cdkn2a -/-NRASQ61K and Ezh2 Δ/Δ Cdkn2a -/-NRASQ61K cells is inhibited by ruxolitinib in an second set of leukemias (See also Figure 7C ).
G: Increased STAT3Y705 phosphorylation in Eed Δ/Δ Cdkn2a -/-NRASQ61K cells compared to flowed counterparts.
H: Eed Δ/Δ Cdkn2a -/-NRASQ61K cells respond to ruxolitinib with growth inhibition in vitro.
I:
Decreased STAT3Y705 phosphorylation and growth in response to the STAT3 inhibitor LLL12.
J:
Decreased STAT3Y705 phosphorylation and growth in response to the STAT3 inhibitor BP-1-102. The effect is accentuated by addition of the drug efflux pump inhibitor verapamil, suggesting pglycoprotein-mediated drug-efflux. For I and J, mean and standard deviation of three experiments are shown. The exposure to LLL12 and BP-1-102/verapamil was repeated with other leukemic and also with pre-leukemic cells, with similar results (data not shown). For exposure to LLL12 and verapamil/ BP-1-102, cells were grown in tissue culture plates in the presence of IL6 and IL7 (1 ng/ml each) and SCF and FLT3L (5 ng/ml each).
Error bars = standard deviation, *p<0.5, NS=not significant. Figure S6 (related to Figure 7) : A: Minor and non-significant increase in Stat3 mRNA in Ezh2 Δ/Δ Cdkn2a -/-NRASQ61K cells (n=3 for each group, 1 pre-leukemic and 2 leukemic). B: Exaggerated response to IL6 stimulation selectively in Ezh2 Δ/Δ Cdkn2a -/-NRASQ61K cells but not to the same degree in Ezh2 f/f Cdkn2a -/-NRASQ61K cells growth factor starved for 8 hours prior to growth factor stimulation. Other growth factors (FLT3, HGF, IL7, SCF) produced less or no detectable STAT3Y705 phosphorylation. Concentration was 10 ng/ml for all growth factors tested. C: Increased STAT3Y705 phosphorylation in HoxA9 transduced cells compared to control (MIG-) transduced in Ezh2 f/f Cdkn2a -/-NRASQ61K cells. Error bars = standard deviation, NS=not significant.
Figure S7 (related to Figure 4 and Figure 5):
Venn diagram of Genes acquiring H3K27me3 in the developmental transitions from DN1 to DP and LSK to GMP (as identified by 'Diffreps') identifies significant overlap. The genes in the overlap are transcriptionally enriched in hematopoietic stem/progenitor cells in 2 published datasets (GSE6506 (Chambers et al., 2007) and GSE18483 (Krivtsov et al., 2013) ).
Supplemental Experimental Procedures Generation of Leukemias
Cells were expanded for 14 -17 days and equal cell numbers of cells for f/f and Δ/Δ (2.5*10 5 -10*10 5 /recipient) were then injected into syngeneic (C57Bl/6) sublethally (600 cGy) irradiated recipients.
Plasmids Used
HR-Cre (Silver and Livingston, 2001) Delta-psi packaging contruct (Naviaux et al., 1996) Genetically Engineered Mice Eed f/f mice (Xie et al., 2014) and Ezh2 f/f mice (Neff et al., 2012) including the lox-STOP-loxROSA26EYFP reporter (Srinivas et al., 2001) were previously described and were crossed to Cdkn2a -/mice (Serrano et al., 1996) . All mice were on a C57Bl/6 background.
Western Blotting
For western blotting, acid extraction of histones was performed using a published method: (http://www.abcam.com/index.html?pageconfig=resource&rid=11410&source=pagetrap&viapagetrap= histoneextraction)
RNA-seq
RNA was isolated using RNAeasy mini columns (Quiagen), and submitted to the UC-Denver genomics core for library preparation and sequencing (Illumina HiSeq2000). RNA-seq pre-injection was performed on Ezh2 Δ/Δ or Ezh2 f/f Cdkn2a -/-NRASQ61K LSK cells grown on OP9DL1 ( (Schmitt et al., 2004) , kindly provided by James DeGregori) in the presence of SCF (5ng/ml), FLT3L (5ng/ml) and IL7 (1 ng/ml). RNA-seq in vivo was performed on RNA from 2x10 5 sorted MAC1-positive blasts harvested from leukemic spleens.
Data Analysis
Raw sequences obtained from RNA-Seq were trimmed and mapped to mm9 using GSNAP. Gene expression was calculated using CuffDiff (Trapnell et al., 2013) . Chip-seq reads were aligned to mm9 using GSNAP. ChIP-seq results were analyzed using Diffreps (Shen et al., 2013) , comparing Ezh2 f/f vs Ezh2 Δ/Δ and murine normal DN1 vs DP (data from (Zhang et al., 2012b) ) cells. The Chip-seq signal heatmap was generated using NGSplot (Shen et al., 2014) . Reads for Gene set enrichment analysis (GSEA, www.broadinstitute.org/gsea) was performed on Genelists pre-ranked based on the log2 of the ratio of expression. Genes with FKPM of <0.5 in both test and control, and genes with FKPM of 0 in one sample and FKPM of < 5 in the other sample were excluded as background. For preranked genelists, genes with FKPM of 0 in one sample and FKPM >5 in the other sample were assigned the log2 value of 20 (if up in ko sample) or -20 (if up in ff sample). Mir and Sno were excluded from genelists for GSEA. Genesets used are described in Table S1 .
Drugs
Ruxolitinib was purchased from LC laboratories (Woburn, MA). LLL12 was purchased from Biovision (Milpitas, CA 95035) and BP-1-102 from Calbiochem/EMD (Billerica, MA). Verapamil was purchased from Sigma-Aldrich, St. Louis, MO).
Genesets for GSEA
The Genesets 'BILD_HRAS_ONCOGENIC_SIGNATURE', and 'KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION' were downloaded from the MSigDB database (http://www.broadinstitute.org/gsea/msigdb/index.jsp) and (Subramanian et al., 2005) .
HSC_mus_up was constructed from (Chambers et al., 2007) (GEO Accession: GSE6506). The Dataset was collapsed and the top 500 genes up in HSC compared to all other tested cell types with a p<0.05 were selected.
HSC_human_up was constructed from (Novershtern et al., 2011 )(GEO Accession: GSE24759). The Dataset was collapsed and the top 500 genes up in HSC compared to all other tested cell types with a p<0.05 were selected.
Human_ETP-ALL was constructed from (Zhang et al., 2012a ) (GEO Accession: GSE28703). The Dataset was collapsed and the top 500 genes up in ETP compared to Typical T-ALL with a p<0.05 were selected. SUZ12_downregulated was constructed from (De Raedt et al., 2014) (GEO Accession: GSE28703). The Dataset was collapsed and the top 500 genes down in Suz12-transduced 90-8TL compared to control transduced cells with a p<0.05 were selected.
DP_only_H3K27me3 was constructed by filtering data from Table S2a in reference (Zhang et al., 2012b) for genes with a ChIP-seq promotor score for H3K27me3 of 0 or 1 (negative to low) in DN1-cells and a ChIP-seq promotor score for H3K27me3 of 2 or 3 (=high) in DP cells.
K27me3 up Ezh2 f/f vs Ezh2 ∆/∆ was constructed by analyzing H3K27me3 ChIP-seq data in Ezh2 f/f vs Ezh2 ∆/∆ NRASQ61K cells. Reads were compared using Diffreps (Shen et al., 2013) . Genes included had decreased signal in Ezh2 ∆/∆ cells, a read count in Ezh2 f/f of > 70, and an association with a Refseq gene (annotation of 'Genebody', 'Promotor 1K', 'Promotor3K' or 'Proximal Promotor').
DN1vsDP_up was constructed by selecting the top 500 genes upregulated in DN1 cells compared to DP cells in the RNA-seq data described in Table S2a of (Zhang et al., 2012b) .
HoxA9_Verhaak was constructed from (Verhaak et al., 2009 )(GEO Accession: GSE6891). The dataset was collapsed and the Pearson correlation coefficient with the HOXA9 probe was calculated for all genes. Genes with a coefficient > or equal 0.4 were selected.
HoxA9_Zhang was constructed from (Zhang et al., 2012a ) (GEO Accession: GSE28703). The dataset was collapsed and the Pearson correlation coefficient with the HOXA9 probe was calculated for all genes. Genes with a coefficient > or equal 0.5 were selected. STAT3-Targets was constructed from (Dauer et al., 2005) . qPCR-validated genes upregulated by STAT3 ( TGCTCCCTGAATGATCACCT mIL6ra_RV GAGAGCTTGGGCTCCTCTG
Table S1
Genesets and genelists
